Misiukiewicz, Krzysztof J.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

Premature discontinuation of curative radiation therapy: Insights from head and neck irradiation

Lazarev, S., Gupta, V., Ghiassi-Nejad, Z., Miles, B., Scarborough, B., Misiukiewicz, K. J., Reckson, B., Sheu, R.-D., & Bakst, R. L. (2018) · Advances in Radiation Oncology

Head and Neck Cancer StudiesAdvances in Oncology and Radiotherapy

Cited by 45

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., et al. (2025) · Cancer Discovery

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 28